Back

Transthyretin (TTR) stabilisation in ATTR cardiomyopathy: myths, measures, and meaning

30 August 2025 (16:30 - 17:30)
Organised by: Logo
Congress Presentation Part of: Transthyretin (TTR) stabilisation in ATTR cardiomyopathy: myths, measures, and meaning Cardiac Amyloidosis ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speakers

Photo
Associate Professor Lorena Saelices Gomez

UT Southwestern Medical Center, Dallas (United States of America)

Photo
Professor Stefano Perlini

University of Pavia, Pavia (Italy)

Access the full session

Session thumbnail
Transthyretin (TTR) stabilisation in ATTR cardiomyopathy: myths, measures, and meaning

The Event

Event poster

ESC Congress 2025

30 August 2025 16:30 CET
You may be interested in
thumbnail
Congress Session
ACT FAST for ATTR-CM: early clues in heart failure to raise clinical suspicion
17 May 2025
thumbnail
Congress Presentation
Exploring the wealth of long-term data for ATTR-CM management​
31 August 2025
thumbnail
Congress Presentation
Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients
27 August 2022
thumbnail
Congress Presentation
Stabilizers of transthyretin in amyloid cardiomyopathy: a systematic review and meta-analysis.
11 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources